Listonstreetpulse.com announces that Arrayit Corporation (OTC: ARYC) has sold its patented and proprietary $1,000 Genome Platform to a leading genomics laboratory in Eastern Europe. The $38,000 purchase order includes a TrayMix™ S4 Microarray Hybridization Station, H25K Whole Human Genome Chips and additional tools, kits and reagents to empower human genome analysis with speed, precision and high sensitivity and specificity.
The $1,000 genome has been a goal of the genomics community since the human genome sequence was completed in 2003, after a 15-year effort and a cost of approximately $3 billion. The Arrayit $1,000 Genome empowers researchers with complete genomic expression information for the entire set of 25,509 genes and >250,000 mRNAs that comprise the human genome.
Researchers and clinicians in university, government, biotechnology, pharmaceutical and Internet companies are increasingly using the Arrayit Microarray Platform to decipher the molecular basis of human disease, identify therapeutic pathways for blockbuster drugs and push the forefront of personalized medicine, which promise to be important drivers of healthcare cost savings and preventative medicine.
ARYC will book revenue and earnings from the platform sale in the current quarter.
To read more about ARYC and subscribe to a monthly update, CEO interview etc, please click here – http://www.listonstreetpulse.com/tag/ARYC/
About Arrayit Corporation
Arrayit Corporation is a Sunnyvale, California-based company leading and empowering the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development, and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. The company’s innovative products and services help scientists and clinicians explore the human genome as well as the genomes of plants and animals. Arrayit’s products are used by every major research center in the world.
About Liston Street Pulse
Liston Street Pulse is a leading provider of financial research. The company has significant expertise in U.S. listed small cap and micro-cap stocks. Over the years, Liston Street Pulse’s original and unbiased analysis has helped the investor community immensely.
